Charlotte Robinson

DocwireNews

Biotechnology company Purespring Therapeutics received approximately $105 million in Series B funding to support the development of gene therapies for diseases of the kidney, including a phase 1/2 trial of an experimental treatment for immunoglobulin A nephropathy (IgAN). The funding came from Forbion, Glide Healthcare, and founding investor Syncona Limited.
Purespring utilizes adeno-associated viruses (AAVs) to transport its gene therapies into the body. The company was established in 2020 to apply AAV gene therapy to the kidney, which can be challenging to target. Other drugmakers, including Vertex Pharmaceuticals and Novartis, are also working on IgAN candidates, although none involve gene therapy.
“Our novel treatment platform and deep understanding of kidney disease puts us in a position to stop, reverse, and even cure kidney disease,” said Purespring’s chief executive officer Julian Hanak in a statement. “The funds raised will allow us to bring our novel treatments to patients in the clinic.”
Purespring presented preclinical data for its AAV gene therapy at the 61st European Renal Association Congress earlier this year and will present IgAN data at the American Society of Nephrology Kidney Week meeting in late October.

Andrew Moreno

Genetic Classification Model Differentiates MDS Stem, Progenitor Cells from Healthy Bone Marrow

ASH 2024

Cecilia Brown

FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line Treatment of ES-SCLC

Small Cell Lung Cancer

Genetic Study Uncovers Potential Therapy-Actionable Transcription Factors in MDS

Latest News

Purespring Receives Funding to Pursue Gene Therapy for IgAN

IgA Nephropathy

Purespring Therapeutics received $105 million in Series B funding to develop gene therapies for kidney diseases, including IgA nephropathy (IgAN).

Purespring Receives Funding to Pursue Gene Therapy for IgAN 

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe